menu ☰
menu ˟

ABSORB China: BVS achieves noninferiority vs. cobalt-chromium everolimus-eluting stent

14 Oct 2015
SAN FRANCISCO — In a multicenter trial to enable approval of the Absorb bioresorbable vascular scaffold in China, the device was noninferior to a cobalt-chromium everolimus-eluting stent for angiographic in-segment late loss at 1 year. “ABSORB Ch...

Click here to view the full article which appeared in Cardiology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.